Export your current network:
... as a vector graphic:
SVG: scalable vector graphic - can be opened and edited in Illustrator, CorelDraw, Dia, etc
... as short tabular text output:
TSV: tab separated values - can be opened in Excel and Cytoscape (lists only one-way edges: A-B)
... as tabular text output:
TSV: tab separated values - can be opened in Excel (lists reciprocal edges: A-B,B-A)
... as an XML summary:
structured XML interaction data, according to the 'PSI-MI' data standard
... protein node degrees:
node degree of proteins in your network (given the current score cut-off)
... network coordinates:
a flat-file format describing the coordinates and colors of nodes in the network
... protein sequences:
MFA: multi-fasta format - containing the aminoacid sequences in the network
... protein annotations:
a tab-delimited file describing the names, domains and descriptions of proteins in your network
... functional annotations:
a tab-delimited file containing all known functional terms of protiens in your network
Browse interactions in tabular form:
| node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
| ERG11 | ERG25 | YHR007C | YGR060W | Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation. | Methylsterol monooxygenase; C-4 methyl sterol oxidase; catalyzes the first of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; mutants accumulate the sterol intermediate 4,4-dimethylzymosterol; human MSMO1 functionally complements the growth defect caused by repression of ERG25 expression. | 0.999 |
| ERG11 | ERG26 | YHR007C | YGL001C | Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation. | Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating; C-3 sterol dehydrogenase; catalyzes the second of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; human homolog NSDHL implicated in CK syndrome, and can complement yeast null mutant; molecular target of natural product and antifungal compound FR171456. | 0.999 |
| ERG11 | ERG27 | YHR007C | YLR100W | Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation. | 3-keto sterol reductase; catalyzes the last of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; mutants are sterol auxotrophs; mutation is functionally complemented by human HSD17B7; Belongs to the short-chain dehydrogenases/reductases (SDR) family. ERG27 subfamily. | 0.999 |
| ERG11 | ERG3 | YHR007C | YLR056W | Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation. | Delta(7)-sterol 5(6)-desaturase; C-5 sterol desaturase; glycoprotein that catalyzes the introduction of a C-5(6) double bond into episterol, a precursor in ergosterol biosynthesis; transcriptionally down-regulated when ergosterol is in excess; mutants are viable, but cannot grow on non-fermentable carbon sources; substrate of HRD ubiquitin ligase; mutation is functionally complemented by human SC5D. | 0.999 |
| ERG11 | ERG6 | YHR007C | YML008C | Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation. | Delta(24)-sterol C-methyltransferase; converts zymosterol to fecosterol in the ergosterol biosynthetic pathway by methylating position C-24; localized to lipid particles, the plasma membrane-associated endoplasmic reticulum, and the mitochondrial outer membrane; Belongs to the class I-like SAM-binding methyltransferase superfamily. Erg6/SMT family. | 0.999 |
| ERG11 | ERG9 | YHR007C | YHR190W | Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation. | Squalene synthase; Farnesyl-diphosphate farnesyl transferase (squalene synthase); joins two farnesyl pyrophosphate moieties to form squalene in the sterol biosynthesis pathway. | 0.999 |
| ERG25 | ERG11 | YGR060W | YHR007C | Methylsterol monooxygenase; C-4 methyl sterol oxidase; catalyzes the first of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; mutants accumulate the sterol intermediate 4,4-dimethylzymosterol; human MSMO1 functionally complements the growth defect caused by repression of ERG25 expression. | Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation. | 0.999 |
| ERG25 | ERG26 | YGR060W | YGL001C | Methylsterol monooxygenase; C-4 methyl sterol oxidase; catalyzes the first of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; mutants accumulate the sterol intermediate 4,4-dimethylzymosterol; human MSMO1 functionally complements the growth defect caused by repression of ERG25 expression. | Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating; C-3 sterol dehydrogenase; catalyzes the second of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; human homolog NSDHL implicated in CK syndrome, and can complement yeast null mutant; molecular target of natural product and antifungal compound FR171456. | 0.999 |
| ERG25 | ERG27 | YGR060W | YLR100W | Methylsterol monooxygenase; C-4 methyl sterol oxidase; catalyzes the first of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; mutants accumulate the sterol intermediate 4,4-dimethylzymosterol; human MSMO1 functionally complements the growth defect caused by repression of ERG25 expression. | 3-keto sterol reductase; catalyzes the last of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; mutants are sterol auxotrophs; mutation is functionally complemented by human HSD17B7; Belongs to the short-chain dehydrogenases/reductases (SDR) family. ERG27 subfamily. | 0.999 |
| ERG25 | ERG3 | YGR060W | YLR056W | Methylsterol monooxygenase; C-4 methyl sterol oxidase; catalyzes the first of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; mutants accumulate the sterol intermediate 4,4-dimethylzymosterol; human MSMO1 functionally complements the growth defect caused by repression of ERG25 expression. | Delta(7)-sterol 5(6)-desaturase; C-5 sterol desaturase; glycoprotein that catalyzes the introduction of a C-5(6) double bond into episterol, a precursor in ergosterol biosynthesis; transcriptionally down-regulated when ergosterol is in excess; mutants are viable, but cannot grow on non-fermentable carbon sources; substrate of HRD ubiquitin ligase; mutation is functionally complemented by human SC5D. | 0.999 |
| ERG25 | ERG6 | YGR060W | YML008C | Methylsterol monooxygenase; C-4 methyl sterol oxidase; catalyzes the first of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; mutants accumulate the sterol intermediate 4,4-dimethylzymosterol; human MSMO1 functionally complements the growth defect caused by repression of ERG25 expression. | Delta(24)-sterol C-methyltransferase; converts zymosterol to fecosterol in the ergosterol biosynthetic pathway by methylating position C-24; localized to lipid particles, the plasma membrane-associated endoplasmic reticulum, and the mitochondrial outer membrane; Belongs to the class I-like SAM-binding methyltransferase superfamily. Erg6/SMT family. | 0.999 |
| ERG25 | ERG9 | YGR060W | YHR190W | Methylsterol monooxygenase; C-4 methyl sterol oxidase; catalyzes the first of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; mutants accumulate the sterol intermediate 4,4-dimethylzymosterol; human MSMO1 functionally complements the growth defect caused by repression of ERG25 expression. | Squalene synthase; Farnesyl-diphosphate farnesyl transferase (squalene synthase); joins two farnesyl pyrophosphate moieties to form squalene in the sterol biosynthesis pathway. | 0.999 |
| ERG26 | ERG11 | YGL001C | YHR007C | Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating; C-3 sterol dehydrogenase; catalyzes the second of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; human homolog NSDHL implicated in CK syndrome, and can complement yeast null mutant; molecular target of natural product and antifungal compound FR171456. | Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation. | 0.999 |
| ERG26 | ERG25 | YGL001C | YGR060W | Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating; C-3 sterol dehydrogenase; catalyzes the second of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; human homolog NSDHL implicated in CK syndrome, and can complement yeast null mutant; molecular target of natural product and antifungal compound FR171456. | Methylsterol monooxygenase; C-4 methyl sterol oxidase; catalyzes the first of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; mutants accumulate the sterol intermediate 4,4-dimethylzymosterol; human MSMO1 functionally complements the growth defect caused by repression of ERG25 expression. | 0.999 |
| ERG26 | ERG27 | YGL001C | YLR100W | Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating; C-3 sterol dehydrogenase; catalyzes the second of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; human homolog NSDHL implicated in CK syndrome, and can complement yeast null mutant; molecular target of natural product and antifungal compound FR171456. | 3-keto sterol reductase; catalyzes the last of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; mutants are sterol auxotrophs; mutation is functionally complemented by human HSD17B7; Belongs to the short-chain dehydrogenases/reductases (SDR) family. ERG27 subfamily. | 0.999 |
| ERG26 | ERG3 | YGL001C | YLR056W | Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating; C-3 sterol dehydrogenase; catalyzes the second of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; human homolog NSDHL implicated in CK syndrome, and can complement yeast null mutant; molecular target of natural product and antifungal compound FR171456. | Delta(7)-sterol 5(6)-desaturase; C-5 sterol desaturase; glycoprotein that catalyzes the introduction of a C-5(6) double bond into episterol, a precursor in ergosterol biosynthesis; transcriptionally down-regulated when ergosterol is in excess; mutants are viable, but cannot grow on non-fermentable carbon sources; substrate of HRD ubiquitin ligase; mutation is functionally complemented by human SC5D. | 0.999 |
| ERG26 | ERG6 | YGL001C | YML008C | Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating; C-3 sterol dehydrogenase; catalyzes the second of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; human homolog NSDHL implicated in CK syndrome, and can complement yeast null mutant; molecular target of natural product and antifungal compound FR171456. | Delta(24)-sterol C-methyltransferase; converts zymosterol to fecosterol in the ergosterol biosynthetic pathway by methylating position C-24; localized to lipid particles, the plasma membrane-associated endoplasmic reticulum, and the mitochondrial outer membrane; Belongs to the class I-like SAM-binding methyltransferase superfamily. Erg6/SMT family. | 0.999 |
| ERG26 | ERG9 | YGL001C | YHR190W | Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating; C-3 sterol dehydrogenase; catalyzes the second of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; human homolog NSDHL implicated in CK syndrome, and can complement yeast null mutant; molecular target of natural product and antifungal compound FR171456. | Squalene synthase; Farnesyl-diphosphate farnesyl transferase (squalene synthase); joins two farnesyl pyrophosphate moieties to form squalene in the sterol biosynthesis pathway. | 0.999 |
| ERG27 | ERG11 | YLR100W | YHR007C | 3-keto sterol reductase; catalyzes the last of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; mutants are sterol auxotrophs; mutation is functionally complemented by human HSD17B7; Belongs to the short-chain dehydrogenases/reductases (SDR) family. ERG27 subfamily. | Lanosterol 14-alpha-demethylase; catalyzes C-14 demethylation of lanosterol to form 4,4''-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway; transcriptionally down-regulated when ergosterol is in excess; member of cytochrome P450 family; associated and coordinately regulated with the P450 reductase Ncp1p; human CYP51A1 functionally complements the lethality of the erg11 null mutation. | 0.999 |
| ERG27 | ERG25 | YLR100W | YGR060W | 3-keto sterol reductase; catalyzes the last of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; mutants are sterol auxotrophs; mutation is functionally complemented by human HSD17B7; Belongs to the short-chain dehydrogenases/reductases (SDR) family. ERG27 subfamily. | Methylsterol monooxygenase; C-4 methyl sterol oxidase; catalyzes the first of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; mutants accumulate the sterol intermediate 4,4-dimethylzymosterol; human MSMO1 functionally complements the growth defect caused by repression of ERG25 expression. | 0.999 |
page 1 of 3